Why Is TANGO THERAPEUTICS I (TNGX) Stock Up Today?

TNGX stock is up 6.10% today, closing the session at $29.32 after opening at $27.74. The rise follows a series of analyst upgrades and a price target increase that has heightened investor interest. The stock reached an intraday high of $29.71 at 10:40 AM ET before settling near that level at the close.

What Happened

Tango Therapeutics (TNGX) saw renewed attention after multiple analysts upgraded their stance on the stock. JP Morgan initiated coverage with an Overweight rating and a $46 price target. Jefferies also upgraded the stock to Buy with a $60 price target. Canaccord Genuity maintained a Buy rating while raising its target to $46. These moves came alongside a recent $600 million public offering of 18,166,667 common shares and 1,833,395 pre-funded warrants priced at $30.00 per share. The offering was upsized from earlier plans, signaling strong demand. The stock traded on 0.5 million shares, which is 0.1 times the 3-month daily average.

What The Data Shows

The stock has moved -4.7% over the last 8 sessions, trading between $30.64 and $29.20. Despite the recent dip, the stock remains within its 52-week range of $5.77 to $34.39. Tango Therapeutics has a market cap of $4.3 billion and is unprofitable with a TTM EPS of -0.86. Revenue has grown 39.0% TTM, but the company continues to operate at a net margin of -188.2%. The stock has a beta of 1.13, indicating slightly higher volatility than the market. In the last 90 days, insiders have sold a total of $1.4 million worth of shares, with the most recent filing on July 2, 2026.

What To Watch

Tango Therapeutics does not have an upcoming earnings date listed. Investors should monitor the breadth of analyst coverage and any further developments in the company’s partnership with KRAS inhibitors, which could influence the stock’s trajectory.